Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Terminated 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Myeloid 3

Conditions

Lymphoma 5Lymphoma, Non-Hodgkin 4Primary Myelofibrosis 3Myeloproliferative Disorders 3Recurrence 2Lymphoma, Follicular 2Hereditary Sensory and Autonomic Neuropathies 2Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1B-Cell Malignancies 1

Interventions

fludarabine phosphate 31Cyclophosphamide 27Mycophenolic Acid 22Whole-Body Irradiation 21Tacrolimus 21ruxolitinib 19Peripheral Blood Stem Cell Transplantation 19Busulfan 19Antilymphocyte Serum 16fludarabine 14Melphalan 12Methotrexate 11Cyclosporine 10thymoglobulin 9Cord Blood Stem Cell Transplantation 7Sirolimus 6Radiotherapy 6Etoposide 6Azacitidine 6Stem Cell Transplantation 5Granulocyte Colony-Stimulating Factor 5Cyclosporins 4pomalidomide 3parsaclisib 3Surveys and Questionnaires 3Rituximab 3Prednisone 3Filgrastim 3Cytarabine 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Primary Myelofibrosis × parsaclisib × Clear all
NCT04551066 2025-10-21

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

Incyte Corporation

Phase 3 Terminated
252 enrolled 18 charts
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT04551053 2025-10-02

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Incyte Corporation

Phase 3 Terminated
177 enrolled 15 charts
Myeloid

Myeloproliferative Disorders, Primary Myelofibrosis

NCT02718300 2024-05-01

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Incyte Corporation

Phase 2 Terminated
74 enrolled 40 charts
Myeloid

Myeloproliferative Disorders, Hereditary Sensory and Autonomic Neuropathies, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡